CreativeOne Wealth LLC Has $1.10 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX

CreativeOne Wealth LLC lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 34.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,815 shares of the company’s stock after selling 4,120 shares during the period. CreativeOne Wealth LLC’s holdings in Neurocrine Biosciences were worth $1,097,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Geneos Wealth Management Inc. increased its position in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after buying an additional 100 shares during the last quarter. Eastern Bank acquired a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $27,000. Quent Capital LLC bought a new position in shares of Neurocrine Biosciences in the third quarter valued at $32,000. Finally, MAI Capital Management grew its stake in shares of Neurocrine Biosciences by 101.2% in the second quarter. MAI Capital Management now owns 328 shares of the company’s stock valued at $41,000 after buying an additional 165 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Truist Financial dropped their price target on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. HC Wainwright decreased their price objective on shares of Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Morgan Stanley restated an “equal weight” rating and set a $175.00 price objective (up from $173.00) on shares of Neurocrine Biosciences in a research note on Thursday, January 8th. JPMorgan Chase & Co. dropped their target price on shares of Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Finally, Wolfe Research started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $175.05.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $129.54 on Thursday. The business has a fifty day simple moving average of $133.57 and a two-hundred day simple moving average of $140.36. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18. The company has a market capitalization of $13.00 billion, a price-to-earnings ratio of 27.80, a P/E/G ratio of 0.68 and a beta of 0.32.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing the consensus estimate of $2.36 by ($0.48). The company had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. Neurocrine Biosciences’s revenue for the quarter was up 28.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.69 earnings per share. As a group, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the transaction, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. This represents a 20.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Leslie V. Norwalk sold 5,000 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $152.23, for a total transaction of $761,150.00. Following the completion of the transaction, the director directly owned 7,429 shares in the company, valued at approximately $1,130,916.67. This represents a 40.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 42,590 shares of company stock worth $5,775,987. 4.80% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.